Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Dyne Therapeutics is leveraging its FORCE platform to target rare neuromuscular diseases with high unmet need. Viking Therapeutics is focused on the massive weight-loss and metabolic market with its clinical-stage candidates.

The Motley Fool • 19 hours ago

VKTX Stock Jumps on Phase I Study Initiation for New Obesity Drug

Viking Therapeutics jumps after it starts its first human study of VK3019, expanding its obesity pipeline with a second candidate alongside its lead program, VK2735.

Zacks Investment Research • Jun 25, 2026

Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $36.97, denoting a -2.38% move from the preceding trading day.

Zacks Investment Research • Jun 25, 2026

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight loss SAN DIEGO, June 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today the initiation of a Phase 1 single ascending dose (SAD) clinical trial of VK3019, an investigational dual amylin and calcitonin receptor agonist (DACRA). VK3019 is being developed as a potential treatment option for weight loss.

PRNewsWire • Jun 24, 2026

Is Viking Therapeutics Stock a No-Brainer Buy Below $35?

Viking Therapeutics is running phase 3 studies for its leading anti-obesity candidate. Its shares could soar from current levels, provided everything goes according to plan.

The Motley Fool • Jun 23, 2026

3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal

Big pharma's appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a question every healthcare portfolio manager is asking: who will be next?

24/7 Wall Street • Jun 23, 2026

Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?

Eli Lilly is already a market leader in the GLP-1 market, but its high valuation could limit future gains. Viking Therapeutics doesn't have an approved product just yet, but VK2735 has shown a lot of promise in clinical trials.

The Motley Fool • Jun 23, 2026

Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk

Viking Therapeutics has a weight-loss program that looks to be competitive with medicines already on the market. It's unclear how its candidate compares to competing programs that are still in clinical trials.

The Motley Fool • Jun 23, 2026

Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know

In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $30.29, indicating a +2.16% shift from the previous trading day.

Zacks Investment Research • Jun 17, 2026

Is Viking Therapeutics Stock Going to $100?

Viking is developing candidates in the high-growth weight loss drug market. The company's lead candidate is involved in late-stage studies.

The Motley Fool • Jun 12, 2026